{"schema_version":"1","generated_at":"2026-11-15T04:23:55.621Z","data_as_of":null,"url":"https://www.findmykol.com/kol/osama-mohamad","json_url":"https://www.findmykol.com/kol/osama-mohamad/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"osama-mohamad","name":"Osama Mohamad","credential":"MD, PhD","specialty":"Radiation Oncology","specialty_raw":"Radiation Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"The University of Texas MD Anderson Cancer Center","institution_url":"https://www.findmykol.com/institution/the-university-of-texas-md-anderson-cancer-center","city":"Houston","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1003226861","orcid":"0000-0003-2972-657X","openalex":"A5004763620"},"summary":"Osama Mohamad is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 180 publications with 3,875 citations (h-index 28).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":180,"cited_by_count":3875,"h_index":28,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"Telix Pharmaceuticals","program_year":2023,"amount_usd":128.48,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1003226861"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1003226861","source":"payments"},"prescribing":{"data_year":2023,"areas_total":1,"areas_shown":1,"areas":[{"area":"Genitourinary & hormones","share_pct":100,"classes_total":2,"classes":[{"class":"alpha-Adrenergic Blocker","setting":"prescribed","share_pct":82.7,"drugs":[{"name":"Tamsulosin Hcl","share_pct":100}],"max_beneficiaries":48},{"class":"beta3-Adrenergic Agonist","setting":"prescribed","share_pct":17.3,"drugs":[{"name":"Myrbetriq","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis","year":2026,"journal":"The Lancet","source_url":"https://doi.org/10.1016/s0140-6736(26)00137-6","status":"verified"},{"title":"Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.24.00365","status":"verified"},{"title":"Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials","year":2025,"journal":"JCO Clinical Cancer Informatics","source_url":"https://doi.org/10.1200/cci-24-00284","status":"verified"},{"title":"Quantification of the environmental impact of radiotherapy and associated secondary human health effects: a multi-institutional retrospective analysis and simulation","year":2024,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(24)00148-7","status":"verified"},{"title":"External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial","year":2024,"journal":"European Urology Oncology","source_url":"https://doi.org/10.1016/j.euo.2024.01.004","status":"verified"}],"source":"works"},"similar":[{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Gabriel Hortobagyi","slug":"gabriel-hortobagyi","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gabriel-hortobagyi","json_url":"https://www.findmykol.com/kol/gabriel-hortobagyi/profile.json"},{"name":"Anil Sood","slug":"anil-sood","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/anil-sood","json_url":"https://www.findmykol.com/kol/anil-sood/profile.json"},{"name":"Jaffer Ajani","slug":"jaffer-ajani","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jaffer-ajani","json_url":"https://www.findmykol.com/kol/jaffer-ajani/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}